Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (281-290 of 740) with videos related to

Pageof 74
Sort By:
Anticancer Research|April 22, 2011
Time to castration resistance is an independent predictor of castration-resistant prostate cancer survivalEvangelos Bournakis, Eleni Efstathiou, Andreas Varkaris, et al.
Oncology|January 18, 2012
A risk-adapted strategy of adjuvant paclitaxel/carboplatin in early-stage ovarian cancer: time-dependent effect of 4 versus 6 cycles on outcomeAristotle Bamias, Christina Bamia, Alexandra Karadimou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasoneMaurizio Zangari, Guido Tricot, Latha Polavaram, et al.
AJR. American Journal of Roentgenology|January 13, 2021
Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of AttenuationVassilis Koutoulidis, Evangelos Terpos, Ioanna Klapa, et al.
Annals of Hematology|May 9, 2020
Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year periodEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Roussou, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 13, 2020
Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III StudiesMichele Cavo, Meletios A Dimopoulos, Jesus San-Miguel, et al.
European Urology|April 21, 2007
Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experienceAristotle Bamias, George Bozas, Nikolaos Antoniou, et al.
Clinical and Experimental Medicine|October 31, 2020
Emerging treatment strategies for COVID-19 infectionMaria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Eleni Korompoki, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 25, 2018
Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström MacroglobulinemiaEvangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Maria Gavriatopoulou, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 30, 2004
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myelomaMeletios A Dimopoulos, George Hamilos, Athanasios Zomas, et al.
Pageof 74

Showing results (281-290 of 740) with videos related to

Sort By:
Pageof 74
Anticancer Research|April 22, 2011
Time to castration resistance is an independent predictor of castration-resistant prostate cancer survivalEvangelos Bournakis, Eleni Efstathiou, Andreas Varkaris, et al.
Oncology|January 18, 2012
A risk-adapted strategy of adjuvant paclitaxel/carboplatin in early-stage ovarian cancer: time-dependent effect of 4 versus 6 cycles on outcomeAristotle Bamias, Christina Bamia, Alexandra Karadimou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasoneMaurizio Zangari, Guido Tricot, Latha Polavaram, et al.
AJR. American Journal of Roentgenology|January 13, 2021
Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of AttenuationVassilis Koutoulidis, Evangelos Terpos, Ioanna Klapa, et al.
Annals of Hematology|May 9, 2020
Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year periodEvangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Roussou, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 13, 2020
Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III StudiesMichele Cavo, Meletios A Dimopoulos, Jesus San-Miguel, et al.
European Urology|April 21, 2007
Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experienceAristotle Bamias, George Bozas, Nikolaos Antoniou, et al.
Clinical and Experimental Medicine|October 31, 2020
Emerging treatment strategies for COVID-19 infectionMaria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Eleni Korompoki, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 25, 2018
Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström MacroglobulinemiaEvangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Maria Gavriatopoulou, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 30, 2004
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myelomaMeletios A Dimopoulos, George Hamilos, Athanasios Zomas, et al.
Pageof 74